secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001493152-23-039445
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus presents Phase 1 Decoy20 interim data: stable disease in all 4 patients
--------------------------------------------------------------------------------

- All four patients in first cohort showed stable disease at 4 weeks; three had progressive disease at baseline.
- Decoy20 induced transient expression of over 50 biomarkers associated with innate/adaptive anti-tumor immune responses.
- Adverse events generally tolerable, resolved within 30 minutes to 3 days; drug cleared from blood in 30-120 minutes.
- Peak cytokine/chemokine induction ~4-24 hours, returning to baseline by 24-48 hours, avoiding prolonged toxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223039445/0001493152-23-039445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223039445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer